Last reviewed · How we verify

Cleocin T — Competitive Intelligence Brief

Cleocin T (CLINDAMYCIN PHOSPHATE) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lincosamide Antibacterial. Area: Immunology.

marketed Lincosamide Antibacterial Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Cleocin T (CLINDAMYCIN PHOSPHATE) — Pfizer. Cleocin T works by inhibiting protein synthesis in bacteria, preventing them from producing essential proteins and ultimately leading to cell death.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cleocin T TARGET CLINDAMYCIN PHOSPHATE Pfizer marketed Lincosamide Antibacterial 1972-01-01
Clindamycin 2-Palmitate CLINDAMYCIN PALMITATE Pfizer marketed Lincosamide Antibacterial 1986-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Lincosamide Antibacterial class)

  1. Pfizer · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cleocin T — Competitive Intelligence Brief. https://druglandscape.com/ci/clindamycin-phosphate. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: